Member Info for Soupdragon78

Zoom market cap is insane at $60+billion, more than all of the airlines operating in the US combined.

Therefore for the share price in zoom to double you are looking for them to add on another $60bn! Whereas for NFX to double you are looking at them adding £20m to the Mcap.

Here’s the thread. Also the company response rns was the same day. 25 Oct.

https://www.lse.co.uk/ShareChat.asp?ShareTicker=NFX&share=Nuformix&thread=FD6B9A7A-1337-4054-A295-803D7544616D&page=3

????

The leak in The Times was 25 October.

Thanks Greggs, unfortunately Nuformix cocrystal work is not really applicable to the other drugs in the Vistagen portfolio as they are singular entities, I.e there are no two crystals to combine.

They are working on Av-101 because it requires the use of Probenecid to be effective. Last year they failed their phase 2 testing using Av-101 on its own, it showed no difference to the placebo in the tests. But they have now found that if the patient takes Probenecid at the same time it does have positive effects.

So it makes sense for them to try and combine the two into one, as they can then patent and produce the final singular drug.

News on NXP004 may still be some weeks away given that the RNS states that the testing was delay by staff and equipment being commandeered.
The UK Biocentre at Milton Keynes is still flat out and isn’t looking like scaling back anytime soon, so it might be a while before Newcastle can resume work.

And just to keep the ball rolling on the thread. Here is CEO of Vistagen talking at Nasdaq last week about what they do.

https://youtu.be/HWvtaxVHO20

Aye chab 2 and a bit posts per day average, really spending a lot of time here.

Although that isn’t using the magic pencil calc method of averages.

Well you OAP’s sure know how to have a fun time spending all day on here.

Anyway since everyone has time to kill, here is Vistagens presentation from a couple of days ago covering AV-101 and Probenecid

https://www.vistagen.com/news-media/multimedia/video/829/bio-international-digital-2020-vistagen-presentation

Agreed finda, it’s been a while since NFX was the subject of a good twitter pump and dump.

Scary, how about posting something informative then, rather than you believe it’ll be huge.

So the names we know associated with Ebers are...

Michael Reynolds - also works at Cannacord and is listed as founder of Ebers
Nigel Little - semi retired ex Cannacord and listed as a director of Ebers
Oliver Little - likely son of Nigel (graduated 2013) worked for clothing brands, listed as ‘sales/analyst’ for Ebers.
DT - Chief Scientific Officer at Ebers since Jan.

Halespur, it’s on DT’s LinkedIn profile. Just google search his name.

Personally I think Ebers was set up by him in part, as it was only incorporated the day before it was RNS’d.

Nice to see that the new Chief Scientific Advisor at Ebers is Dave Tapolczay.

Lol!!!

“The deal has been lost but I thinks it’s worth buying at this price”

Not much of an agenda there.

Best wishes to you and your grandchild goup and hope you achieve your goals.

One thing the disparity of opinions here definitely shows, is that nobody on this board has a clue what is actually happening, hence everyone is talking their own agenda.

Thanks Greggs, if as you say it is a political aspect then this will no doubt only be finalised with face to face discussion, so we will be waiting for travel quarantine rules to be relaxed before any progress.

Jay, my point was in response to the very specific comment that Dan knows the Kissei board, which is still an unsubstantiated claim, there is nothing in the public realm to back this up, only supposition.

Like you, I am positive on the potential outcome, but I do think it will be a number of months yet given how badly the government are handling the Covid situation.

Hope your right Greggs, although I’ve not seen any evidence that he has any contact with kissei.

Positive moves today though is worth being happy about. Nearly as good as watching Colston take a dip.

Greggs, you say Dan is close to Kissei, in what context?

I don’t know enough about the CINV market that NXP001 is targeting to say whether Kissei would be interested. I doubt it as all the talk to date have been about a generics company being interested.

Furthermore, my sceptical side doubts whether Kissei are one of the parties on NXP002 discussions.

If you are an insider going to feed a story to a newspaper, you don’t name the actually company involved as that would risk scuppering any prospective deal. What you would likely do is name someone who you knew wasn’t interested to spook your bidder into thinking they are.

But like everyone else, I’m none the wiser. It’s all just supposition.